<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04481607</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3454-I-02</org_study_id>
    <nct_id>NCT04481607</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets</brief_title>
  <official_title>A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics
      of TQB3454 tablets in subjects with advanced solid tumor or hematologic tumor.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>MTD was defined as the dose in which more than 2 of up to 6 patients developed a DLT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose;</time_frame>
    <description>Cmax is the maximum plasma concentration of TQB3454 or metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose;</time_frame>
    <description>To characterize the pharmacokinetics of TQB3454 by assessment of time to reach maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Hour 0(pre-dose), 0.5, 1, 2, 3, 5, 8, 10, 24, 48, 72, 120, 168 hours post-dose on single dose;</time_frame>
    <description>To characterize the pharmacokinetics of TQB3454 by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 60 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hydroxyglutaric acid</measure>
    <time_frame>Hour 0(pre-dose) on single dose; Hour 0(pre-dose) of day1, day8, day15, day28 on multiple dose of first cycle; hour 0(pre-dose) of day15, day28 of second and third cycle; hour 0(pre-dose) of day28 of fourth to eighth cycle.</time_frame>
    <description>Correlation between 2-hydroxyglutaric acid and efficacy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Advanced Solid Tumor or Hematologic Tumor</condition>
  <arm_group>
    <arm_group_label>TQB3454 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3454</intervention_name>
    <description>TQB3454 tablets is a small molecule oral drug.</description>
    <arm_group_label>TQB3454 tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; Life
        expectancy ≥12 weeks.

        2. Advanced solid tumors or hematological malignancy. 3. Adequate laboratory indicators. 4.
        No pregnant or breastfeeding women, and a negative pregnancy test. 5. Understood and Signed
        an informed consent form.

        Exclusion Criteria:

          -  1. Has central nervous system metastasis or system leukemia. 2.Previous anti-tumor
             treatment:

               1. Has received IDH1 mutation inhibitor.

               2. Has received systemic anti-tumor therapy or radiotherapy within 14 days before
                  the first dose.

               3. Has received oral targeted drugs, less than 5 drug half-lives from first dose.

               4. The related toxicity of previous anti-tumor therapy has not recovered to CTCAE ≤
                  grade 2, except for hair loss.

                  3.Complicated disease and medical history:

               1. Active hepatitis B or hepatitis C.

               2. Abnormal kidney.

               3. Abnormal cardiovascular and cerebrovascular.

               4. Abnormal gastrointestinal.

               5. Has medical history of immunodeficiency.

               6. Has bleeding (hemoptysis), coagulopathy, or been using warfarin, aspirin, and
                  other antiplatelet agglutination drugs.

               7. Has uncontrollable systemic bacterial, fungal or viral active infections.

               8. Has medical history of idiopathic pulmonary fibrosis,or tissue pneumonia.

               9. Has allergic constitution or previous severe allergy; or known allergy to
                  ingredients of study drug.

              10. Has neurological or mental disorders.

              11. Has a history of drug abuse or drug addict.

              12. Has received major surgery, open biopsy, or obvious traumatic injury within 4
                  weeks before the first dose.

              13. According to the judgement of the researchers, there are other factors that
                  subjects are not suitable for the study.

                  4. Has participated in other clinical trials within 30 days before participating
                  in this trial.

                  5. Female patients during pregnancy or lactation. 6. According to the judgement
                  of the researchers, there are other factors that subjects are not suitable for
                  the study.

                  7. criteria for solid tumors:

               1. Has any signs of bleeding constitution.

               2. Has any CTCAE ≥ grade 3 bleeding or bleeding event,within 4 weeks before the
                  first dose.

               3. Has unhealed wounds, fractures, active ulcers of the stomach and duodenum,
                  ulcerative colitis and other digestive tract diseases.

               4. Imaging (CT or MRI) shows that the tumor has invaded the circumference of
                  important blood vessels.

               5. Has uncontrollable pleural effusion, pericardial effusion or ascites that still
                  need repeated drainage.

        criteria for blood tumor:

        a) Has severe life-threatening leukemia complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Shen, Doctor</last_name>
    <phone>010-88196340</phone>
    <email>doctorshenlin@sina.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin Shen, Doctor</last_name>
      <phone>010-88196340</phone>
      <email>doctorshenlin@sina.cn</email>
    </contact>
    <investigator>
      <last_name>Lin Shen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 19, 2020</study_first_submitted>
  <study_first_submitted_qc>July 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>July 19, 2020</last_update_submitted>
  <last_update_submitted_qc>July 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

